<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767089</url>
  </required_header>
  <id_info>
    <org_study_id>A9001309</org_study_id>
    <nct_id>NCT02767089</nct_id>
  </id_info>
  <brief_title>The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-controlled, Crossover Studyto Assess The Dose Response Of Prednisone On Biochemical Andclinical Markers Of Efficacy And Safety In Adult Healthyvolunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further access the utility of biochemical and clinical
      biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against
      which dissociated agonists of the glucocorticoid receptor (DAGR) will be evaluated in adult
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on osteocalcin</measure>
    <time_frame>8 days</time_frame>
    <description>The change in serum osteocalcin from baseline after treatment on Day 1 and Day 8 will be assessed in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Cortisol Suppression</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in serum cortisol after treatment on Day 1 and Day 8 in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on HPA Axis Suppression</measure>
    <time_frame>14 days after the last study visit in Period 3, if repeat testing required will be done 28 days after first test</time_frame>
    <description>Serum cortisol in response to low-dose ACTH Stimulation Test will be completed at the end of Period 3 for each subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on White Blood Cell Counts</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in blood leukocytes (neutrophils, lymphocytes and eosinophils) in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Procollagen type 1-N-Propeptide (P1NP)</measure>
    <time_frame>8 days</time_frame>
    <description>The change from baseline in serum P1NP after treatment on Day 1 and Day 8 will be assessed in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Urinary N-terminal cross-linked telopeptide of type 1 collagen (uNTX-1)</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in uNTX-1 will be assessed on Day 1 and Day 8 after treatment in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Fasting glucose and insulin</measure>
    <time_frame>8 days</time_frame>
    <description>Glucose and insulin will be assessed for the change from baseline after 7 days of treatment on Day 8 in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on an Oral Glucose Tolerance Test</measure>
    <time_frame>Day 6</time_frame>
    <description>On Day 6 of each period, subjects will undergo an oral glucose tolerance test. After ingesting 75 g of a glucose solution within 5 minutes of receiving their daily dose of prednisone, blood samples for glucose were obtained at 0.5, 1 and 2 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Triglycerides</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in triglycerides will be assessed after 7 days of treatment on Day 8 in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Urinary Cortisol Suppression</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline in 24-hour urinary cortisol on Day 7 in each treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Adiponectin</measure>
    <time_frame>8 days</time_frame>
    <description>Change from baseline in adiponectin will be assessed after 7 days of treatment on Day 8 in each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Profile of Mood State</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline after 7 days of treatment in each treatment period. The POMS is a copyrighted questionnaire that measures 6 dimensions of mood. The subject will assess how 65 descriptors apply to him/her on a 5-point scale of 0 (not at all) to 4 (extremely).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Medical Outcomes: Sleep Scale (MOS-Sleep)</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline in sleep after 7 days of treatment will be assessed in each treatment period. The patient-reported questionnaire consists of 12 items that assesses the key constructs of sleep. Scores can range from 12-71 with higher number indicating more problems with sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on the Incidence of Adverse Events</measure>
    <time_frame>28 days after last dose of study medication in Period 3</time_frame>
    <description>Subjects were monitored throughout the study and queried for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Blood Pressure</measure>
    <time_frame>8 days</time_frame>
    <description>Blood pressure will be assessed for change from baseline after 7 days of treatment on Day 8 in each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on Weight</measure>
    <time_frame>8 days</time_frame>
    <description>A post-void weight will be collected on the morning of Day 1 and Day 8 to assess change from baseline during each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response effect of prednisone 2.5, 5, 10, 20, 40 and 60 mg on pulse rate</measure>
    <time_frame>8 days</time_frame>
    <description>Pulse rate will be assessed for change from baseline after 7 days of treatment on Day 8 in each treatment period</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence G</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <arm_group_label>Sequence G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females willing to be confined and comply with scheduled visits

          -  Women are to be surgically sterile.

        Exclusion Criteria:

          -  History of febrile illness within 5 days prior to the first dose

          -  Positive urine drug screen

          -  Treatment with an investigational product within 30 days prior to the first dose of
             study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jasper Clinic, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucocorticoids, Biomarkers, Dissociated Agonist of the Glucocorticoid Receptor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

